2 Fast-Growing Pharmaceutical Stocks to Buy Now

Incyte is forecasting four new approvals/launches through early 2027 after expanding its late-stage pipeline with a $1.25B acquisition of Vega Therapeutics. Q1 results were strong: revenue rose 21% YoY to $1.27B and EPS increased to $1.47 (up 83.7%), with adjusted EPS of $1.81 beating the $1.34 consensus; Jakafi sales were $758M (+7%) and Opzelura $143M (+20%). Separately, TG Therapeutics’ Briumvi momentum continues as management raised full-year revenue guidance to $925M after $194.8M of Q1 U.S. sales, while the stock is up nearly 90% in 2026.

Analysis

INCY is the cleaner quality story: free cash flow plus a broader shot profile can support multiple expansion only if the market starts to believe the launch cadence is real rather than aspirational. The key mechanism is not this quarter’s beat; it is whether management can convert pipeline breadth into a lower concentration discount over the next 12-18 months. If that happens, the stock can re-rate even without heroic top-line growth.

TGTX has the opposite setup: a strong commercial asset has already pulled forward a lot of future optimism, so the burden of proof shifts to persistence, label expansion, and any credible strategic premium. In the next 1-3 months, the biggest risk is that the market prices in a takeout that may never arrive, while payer pressure and MS competition can slow the next leg of growth. Biogen is the most obvious relative loser if Briumvi continues to take share, but that only matters if the growth curve stays steep enough to matter at scale.

Contrarian view: the market is treating acquisition optionality as if it were cash flow. In biotech, buyers usually pay for de-risked, broad labels, not just a good commercial franchise; that makes TGTX’s M&A premium more fragile than it looks. The more attractive relative value is owning INCY’s diversification path versus paying up for TGTX’s already-momentum-priced single-asset story; falsifiers are a TGTX bid, another guidance raise, or an INCY launch slip / pipeline setback.

Key Decisions for Investors

• Long INCY / short TGTX as a 3-6 month relative-value pair: INCY has lower execution risk and more runway to multiple expansion; TGTX already discounts a lot of good news. Cover the short if TGTX announces a formal strategic process or if incremental sales guidance steps up again.
• Buy INCY on pullbacks after event-driven weakness, not into strength; the 6-18 month catalyst path is pipeline conversions and label expansion, not headline chatter. Thesis breaks if Jakafi/Opzelura decelerate materially or if late-stage readouts push approvals beyond 2027.
• Avoid chasing TGTX after its run; for holders, consider trimming or overlaying short-dated call spreads to monetize elevated expectations over the next 1-2 quarters. Reassess only if subcutaneous conversion data clearly improves persistence or an unsolicited bid appears.
• Watch BIIB as a defensive hedge to TGTX momentum: if Briumvi share gains accelerate, BIIB is the cleaner short on MS competitive pressure, but only on evidence of sustained share shift rather than a single quarter.